# A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

> **NCT07662135** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 900 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Type 2 Diabetes With Chronic Kidney Disease

## Interventions

- **DRUG:** Elecoglipron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07662135
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-06
- **Primary completion:** 2028-07-13
- **Final completion:** 2028-07-13
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2026-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662135, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07662135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*